Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. StemCell Institute's
Operating Income
for the
three
months ended in Mar. 2026 was 円-16 Mil. StemCell Institute's Interest Expense for the
three
months ended in Mar. 2026 was 円-2 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for StemCell Institute's Interest Coverage or its related term are showing as below:
TSE:7096'
s Interest Coverage Range Over the Past 10 Years
Min: 25.46 Med: No Debt Max: No Debt
Current: 25.46
TSE:7096's Interest Coverage is ranked worse than 64.29% of 378
companies
in the Biotechnology industry
Industry Median: 105.09
vs TSE:7096: 25.46
StemCell Institute (TSE:7096) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
StemCell Institute Interest Coverage Related Terms
StemCell Institute Interest Coverage Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TSE:7096 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, StemCell Institute's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Interest Coverage distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
StemCell Institute did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
StemCell Institute (TSE:7096) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on StemCell Institute and its competitors. Over the past decade, StemCell Institute's Interest Coverage has ranged from 25.46 to 10,000.00. According to the industry distribution chart, StemCell Institute ranks #243 out of 378 companies in the Biotechnology industry, placing it in the top 64.3%.
Is StemCell Institute's Interest Coverage too high?
StemCell Institute's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 25.46 to a high of 10,000.00. Based on the distribution chart, StemCell Institute ranks #243 out of 378 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCell Institute has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #243 out of 378 companies for Interest Coverage. This places StemCell Institute in the lower half of its industry. The industry median Interest Coverage is 105.09. Historically, StemCell Institute's own Interest Coverage has ranged from 25.46 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 105.09, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median Interest Coverage is 105.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,837.46, compared to a current price of 円766.00 — trading 58.3% below its estimated fair value. The current Interest Coverage is 0 (At Loss). StemCell Institute's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円766.00 is trading 58.3% below its estimated GF Value™ of 円1,837.46.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Interest Coverage: 0 (At Loss)
GF Value™: 円1,837.46 vs. price of 円766.00 (58.3% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
68GF Score
Get the complete analysis for TSE:7096
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
